SEC Company Response from Corbus Pharmaceuticals Holdings, Inc. (CRBP) (CIK 0001595097) (CRBP) — Jan 16, 2018

Corbus Pharmaceuticals Holdings, Inc. (CRBP) (CIK 0001595097)
Date: Jan. 16, 2018 · CIK: 0001595097 · Accession: 0001493152-18-000581

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-222447

Date

January 5, 2018

Author

Chief

Form

CORRESP

Company

Corbus Pharmaceuticals Holdings, Inc. (CRBP) (CIK 0001595097)

Letter

Corbus Pharmaceuticals Holdings, Inc.

River Ridge Drive

Norwood, MA 02062

January 16, 2018

VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

F Street, N.E.

Washington, D.C. 20549

Re: Corbus Pharmaceuticals Holdings, Inc.

Registration Statement on Form S-3 (File No. 333-222447)

Filed on January 5, 2018

Ladies and Gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended, Corbus Pharmaceuticals Holdings, Inc. (the “Company”) hereby requests that the above-referenced Registration Statement (the “Registration Statement”) be declared effective by the Securities and Exchange Commission (the “Commission”) at 4:30 p.m., Eastern Standard Time, on January 17, 2018, or as soon as practicable thereafter.

Please call Steven M. Skolnick of Lowenstein Sandler LLP at (973) 597-2476 to confirm the effectiveness of the Registration Statement or with any questions.

[Signature page follows.]

U.S. Securities and Exchange Commission

January 16, 2018

Page

Very truly yours,
CORBUS PHARMACEUTICALS

Show Raw Text

CORRESP
1
filename1.htm

Corbus
Pharmaceuticals Holdings, Inc.

100
River Ridge Drive

Norwood,
MA 02062

January
16, 2018

VIA
EDGAR

United
States Securities and Exchange Commission

Division
of Corporation Finance

100
F Street, N.E.

Washington,
D.C. 20549

    Re:
    Corbus
    Pharmaceuticals Holdings, Inc.

    Registration
    Statement on Form S-3 (File No. 333-222447)

    Filed
    on January 5, 2018

Ladies
and Gentlemen:

In
accordance with Rule 461 under the Securities Act of 1933, as amended, Corbus Pharmaceuticals Holdings, Inc. (the “Company”)
hereby requests that the above-referenced Registration Statement (the “Registration Statement”) be declared
effective by the Securities and Exchange Commission (the “Commission”) at 4:30 p.m., Eastern Standard Time,
on January 17, 2018, or as soon as practicable thereafter.

Please
call Steven M. Skolnick of Lowenstein Sandler LLP at (973) 597-2476 to confirm the effectiveness of the Registration Statement
or with any questions.

[Signature
page follows.]

U.S.
Securities and Exchange Commission

January
16, 2018

Page
2

    Very truly yours,

    CORBUS PHARMACEUTICALS

    HOLDINGS, INC.

    By:
    /s/
    Sean Moran

    Name:
    Sean
    Moran

    Title:

    Chief
    Financial Officer

    -2-

SecProbe.io